Quest Laboratories Ltd (QUESTLAB) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Quest Laboratories Ltd on NSE and BSE, with an AI summary of each filing.
QUEST LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 11-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 11 Nov 2026, 5:30 am
Quest Laboratories Schedules Board Meeting for Half-Yearly Results on 11th Nov'26 Quest Laboratories Limited has notified the stock exchange that its Board of Directors will meet on 11th Nov'26. The board will inter-alia consider, review, and approve the company's unaudited financial results for the half-year ended Sep'26.
To consider and approve the financial results for the period ended September 30, 2026 and other business matters
Intimation · 11 Nov 2026, 5:30 am
Quest Laboratories Schedules Board Meeting on 11th Nov'26 to Consider Half-Year Results Quest Laboratories Limited has scheduled its Board of Directors meeting for 11th Nov'26 to consider and approve the unaudited financial results for the half year ended 30th Sep'26. Additionally, the company's trading window for designated insiders, which closed on 1st Oct'26, will remain shut until 48 hours following the official declaration of the half-yearly financial results.
Quest Laboratories Limited has informed the Exchange regarding voting results of Annual General Meeting held on September 29, 2025
Annual General Meeting · 03 Oct 2026, 9:41 pm
Proceedings of the 28th Annual General Meeting
Annual General Meeting · 30 Sept 2026, 11:46 pm
Quest Laboratories Limited has informed the Exchange regarding 'Intimation regarding Strategic Collaboration.'.
Others (Uncategorized) · 29 Sept 2026, 2:18 pm
Quest Laboratories Partners With Niraga Capitals for Strategic Growth Quest Laboratories Limited has commenced a strategic advisory collaboration with Niraga Capitals Private Limited to accelerate business expansion, export development, and corporate institutionalisation. Niraga Capitals will advise on foreign commercial alliances, institutional hospital and government tenders, contract manufacturing, and portfolio expansion. Additionally, the partnership will evaluate inorganic growth routes—including M&A, joint ventures, and licensing—alongside capital structuring alternatives such as private equity, structured capital, and debt to fund working capital and manufacturing capacity additions. Quest will retain full operational and statutory responsibilities.
Quest Laboratories Limited has informed the Exchange regarding 'Business Update Order Book Position'.
Others (Uncategorized) · 29 Sept 2026, 2:14 pm
Quest Laboratories Reports Current Order Book Position at ₹39.73 Crores Quest Laboratories Limited disclosed a business update reporting its total order book position at ₹39.73 Crores as of 28th Sep'26. For the upcoming third quarter, the company secured export orders worth ₹10.71 Crores and booked domestic sales amounting to ₹16.90 Crores, driven by its ongoing focus on expanding both domestic and export market operations.
Quest Laboratories Limited has informed the Exchange regarding 'Update on Expansion of Manufacturing Facilities'.
Others (Uncategorized) · 29 Sept 2026, 2:11 pm
Quest Laboratories Announces Progress and Operationalization in Facility Expansions Quest Laboratories operationalized its Phase-I manufacturing expansion on 16th Sep'26, adding a ~12,000 sq. ft. building featuring a finished goods warehouse, blister packing line, and a quality control section. Additionally, civil construction for its Phase-II Injection Section expansion was completed in Sep'26. Clean room installations are underway, with injection machinery expected by end-Dec'26 and trial runs slated for Jan-Feb'27, strengthening the company's overall manufacturing capabilities for future business growth.
Quest Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on September 04, 2026, to consider and approve Notice of 28th Annual General Meeting.
Outcome · 04 Sept 2026, 9:02 pm
Quest Laboratories Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI (Listing Obligations and DisclosureRequirements) Regulations, 2015 Execution of Strategic Growth, Marketing, BusinessDevelopment, and Investment Facilitation Agreement'.
Others (Uncategorized) · 31 Jul 2026, 4:27 am
Quest Laboratories Engages Strategic Partners for 5-Year Growth and Mainboard Listing Quest Laboratories signed a 5-year strategic agreement on 22 Jul'26 with Niraga Capitals and a consortium for growth, marketing, and fundraising. The consortium will receive a 30% commission on annual EBITDA growth (50% cash, 50% equity) and up to 9% equity dilution based on achieving market cap milestones from ₹250 Cr to ₹1,000 Cr. Fundraising success fees are 5% for equity/M&A and 3% for debt. The agreement aims to scale operations, expand exports, and prepare for an NSE mainboard listing.
Quest Laboratories Limited has informed the Exchange regarding 'Intimation regarding change in frequency of disclosure of Financial Results from Quarterly to Half-Yearly basis under Regulation 33 of SEBI (LODR) Regulations, 2015'.
Others (Uncategorized) · 02 Jul 2026, 1:46 am
Quest Laboratories Shifts to Half-Yearly Financial Reporting Quest Laboratories Limited, an SME-listed entity, is shifting its financial disclosure frequency from quarterly to half-yearly, effective from FY 2026-27. The company had voluntarily adopted quarterly reporting for FY 2025-26 but will now align with the standard SME platform requirement under SEBI regulations. This change aims to streamline administrative timelines. The first half-yearly results will be for the period ending 30 Sep'26, followed by annual audited results for the year ending 31 Mar'27, adhering to prescribed timelines.